Peak VO2 et al. for prognosis in heart failure? [3] (multiple letters)

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 591-592

  Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC VALUE; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; BLOOD; BLOOD GAS ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; FOLLOW UP; NOTE; PROGNOSIS; REPRODUCIBILITY;

BIOLOGICAL MARKER; OXYGEN;

BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; OXYGEN; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 0033071167     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (14)

1. Linzbach A.J. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960;370-382.
2. Cohn J.N. Structural basis for heart failure ventricular remodeling and its pharmacological inhibition. Circulation. 91:1995;2504-2507.
3. Linzbach AJ. Fifth Freiburger Symposium. Springer Verlag. Berlin, 1958. p. 94.
4. Gerdes AM, Kellerman SE, and Schocken DD. Implications of cardiomyocyte remodeling in heart dysfunction. In: The Failing Heart. Eds. Dhalla NS, Beamish RE, Takeda N, Nagano M. Lippincott-Raven. Philadelphia, New York, pp. 197-205.
5. Gerdes A.M., Kellerman S.E., Moore J.A., et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 86:1992;426-430.
6. Katjstura J., Leri A., Finato N., Di Loreto C., Beltrami C.A., Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci. 95:1998;8801-8805.
7. Cohn J.N., Francis G.S. Cardiac failure a revised paradigm. J Card Failure. 1:1995;261-266.
8. Fuster V., Gersh B.J., Giuliani E.R., Tajik A.J., Bradenburg R.O., Frye R.L. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 47:1981;525-531.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
10. Al-Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., Konstam M.A. Warfarin anticoagulation and survival a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 31:1998;749-753.
11. Baker D.W., Wright R.F. Management of heart failure IV anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA. 272:1994;1614-1618.
12. Koniaris L.S., Goldhaber S.Z. Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol. 31:1998;745-748.
13. Grünig E., Tasman J.A., Kücherer H., Franz W., Kübler W., Katus H.A. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 31:1998;186-194.
14. Baig M.K., Goldman J.H., Caforio A.L.P., Coonar A.S., Keeling P.J., McKenna W.J. Familial dilated cardiomyopathy cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol. 31:1998;195-201.